Manish Sagar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2300266/publications.pdf

Version: 2024-02-01

257450 161849 4,105 58 24 54 citations h-index g-index papers 64 64 64 7697 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. New England Journal of Medicine, 2020, 383, 2333-2344.	27.0	1,102
2	Recent endemic coronavirus infection is associated with less-severe COVID-19. Journal of Clinical Investigation, $2021,131,131$	8.2	277
3	Human Immunodeficiency Virus Type 1 V1-V2 Envelope Loop Sequences Expand and Add Glycosylation Sites over the Course of Infection, and These Modifications Affect Antibody Neutralization Sensitivity. Journal of Virology, 2006, 80, 9586-9598.	3.4	267
4	Long-Term Reduction in Peripheral Blood HIV Type 1 Reservoirs Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation. Journal of Infectious Diseases, 2013, 207, 1694-1702.	4.0	250
5	Selection for Human Immunodeficiency Virus Type 1 Envelope Glycosylation Variants with Shorter V1-V2 Loop Sequences Occurs during Transmission of Certain Genetic Subtypes and May Impact Viral RNA Levels. Journal of Virology, 2005, 79, 6528-6531.	3.4	241
6	Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1. Annals of Internal Medicine, 2014, 161, 461.	3.9	225
7	Transmission ofHistoplasma capsulatumby Organ Transplantation. New England Journal of Medicine, 2000, 343, 1163-1166.	27.0	139
8	Infection with Multiple Human Immunodeficiency Virus Type 1 Variants Is Associated with Faster Disease Progression. Journal of Virology, 2003, 77, 12921-12926.	3.4	133
9	Selection of HIV Variants with Signature Genotypic Characteristics during Heterosexual Transmission. Journal of Infectious Diseases, 2009, 199, 580-589.	4.0	130
10	p53 and Tumor Necrosis Factor \hat{l}_{\pm} Regulate the Expression of a Mitochondrial Chloride Channel Protein. Journal of Biological Chemistry, 1999, 274, 36488-36497.	3.4	119
11	In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Subject. Journal of Virology, 2008, 82, 8210-8214.	3.4	110
12	Human Immunodeficiency Virus Type 1 (HIV-1) Diversity at Time of Infection Is Not Restricted to Certain Risk Groups or Specific HIV-1 Subtypes. Journal of Virology, 2004, 78, 7279-7283.	3.4	76
13	In Vivo Fitness Cost of the M184V Mutation in Multidrug-Resistant Human Immunodeficiency Virus Type 1 in the Absence of Lamivudine. Journal of Virology, 2009, 83, 2038-2043.	3.4	76
14	Previously Transmitted HIV-1 Strains Are Preferentially Selected During Subsequent Sexual Transmissions. Journal of Infectious Diseases, 2012, 206, 1433-1442.	4.0	71
15	Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257. Clinical Infectious Diseases, 2015, 60, 1842-1851.	5.8	67
16	HIVâ€1 Transmission Biology: Selection and Characteristics of Infecting Viruses. Journal of Infectious Diseases, 2010, 202, S289-S296.	4.0	63
17	Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge. International Journal of Infectious Diseases, 2020, 99, 28-33.	3.3	62
18	Identification of modifiable factors that affect the genetic diversity of the transmitted HIV-1 population. Aids, 2004, 18, 615-619.	2.2	60

#	Article	IF	Citations
19	HIV-1 replicates and persists in vaginal epithelial dendritic cells. Journal of Clinical Investigation, 2018, 128, 3439-3444.	8.2	56
20	Human Immunodeficiency Virus Type 1 V1-to-V5 Envelope Variants from the Chronic Phase of Infection Use CCR5 and Fuse More Efficiently than Those from Early after Infection. Journal of Virology, 2009, 83, 9694-9708.	3.4	41
21	No Evidence for Rapid Subtype C Spread within an Epidemic in Which Multiple Subtypes and Intersubtype Recombinants Circulate. AIDS Research and Human Retroviruses, 2005, 21, 1060-1065.	1.1	38
22	Transmembrane Domain Membrane Proximal External Region but Not Surface Unit–Directed Broadly Neutralizing HIV-1 Antibodies Can Restrict Dendritic Cell–Mediated HIV-1 Trans-infection. Journal of Infectious Diseases, 2012, 205, 1248-1257.	4.0	38
23	Origin of the Transmitted Virus in HIV Infection: Infected Cells Versus Cell-Free Virus. Journal of Infectious Diseases, 2014, 210, S667-S673.	4.0	33
24	Maternal but Not Infant Anti-HIV-1 Neutralizing Antibody Response Associates with Enhanced Transmission and Infant Morbidity. MBio, $2017,8,.$	4.1	32
25	Effect of Contraceptive Methods on Natural History of HIV: Studies from the Mombasa Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 38, S18-S20.	2.1	24
26	Diversity in HIV-1 Envelope V1–V3 Sequences Early in Infection Reflects Sequence Diversity Throughout the HIV-1 Genome But Does Not Predict the Extent of Sequence Diversity During Chronic Infection. AIDS Research and Human Retroviruses, 2006, 22, 430-437.	1.1	24
27	Evolution of CCR5 Antagonist Resistance in an HIV-1 Subtype C Clinical Isolate. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 420-427.	2.1	23
28	Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants. EBioMedicine, 2016, 8, 237-247.	6.1	22
29	Cooperation of p53 loss of function and v-Ha-ras in transformation of mouse keratinocyte cell lines. Molecular Carcinogenesis, 1998, 21, 50-61.	2.7	20
30	Env sequence determinants in CXCR4-using human immunodeficiency virus type-1 subtype C. Virology, 2012, 433, 296-307.	2.4	20
31	HIV-1 Transcription but Not Intact Provirus Levels are Associated With Systemic Inflammation. Journal of Infectious Diseases, 2021, 223, 1934-1942.	4.0	19
32	HIV-1 envelope replication and $\hat{1}\pm4\hat{1}^27$ utilization among newly infected subjects and their corresponding heterosexual partners. Retrovirology, 2013, 10, 162.	2.0	18
33	Refining the treatment of women with unstable angina—A randomized, doubleâ€blind, comparative safety and efficacy evaluation of integrelinâ"¢ versus aspirin in the management of unstable angina. Clinical Cardiology, 1996, 19, 869-874.	1.8	16
34	Clinical outcomes and inflammatory marker levels in patients with Covid-19 and obesity at an inner-city safety net hospital. PLoS ONE, 2020, 15, e0243888.	2.5	16
35	Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection Associates With Unstable Housing and Occurs in the Presence of Antibodies. Clinical Infectious Diseases, 2022, 75, e208-e215.	5.8	16
36	Sensitivity Changes over the Course of Infection Increases the Likelihood of Resistance Against Fusion but Not CCR5 Receptor Blockers. AIDS Research and Human Retroviruses, 2012, 28, 1584-1593.	1.1	15

#	Article	IF	CITATIONS
37	Single genome amplification and standard bulk PCR yield HIV-1 envelope products with similar genotypic and phenotypic characteristics. Journal of Virological Methods, 2015, 214, 46-53.	2.1	15
38	Pre-existing infant antibody-dependent cellular cytotoxicity associates with reduced HIV-1 acquisition and lower morbidity. Cell Reports Medicine, 2021, 2, 100412.	6.5	15
39	HIV-1 Coreceptor Usage and Variable Loop Contact Impact V3 Loop Broadly Neutralizing Antibody Susceptibility. Journal of Virology, 2020, 94, .	3.4	14
40	Characterization of HIV-1 envelopes in acutely and chronically infected injection drug users. Retrovirology, 2014, 11, 106.	2.0	13
41	Coronavirus Disease 2019 Mitigation Strategies Were Associated With Decreases in Other Respiratory Virus Infections. Open Forum Infectious Diseases, 2021, 8, ofab105.	0.9	13
42	Novel ELISA Protocol Links Pre-Existing SARS-CoV-2 Reactive Antibodies With Endemic Coronavirus Immunity and Age and Reveals Improved Serologic Identification of Acute COVID-19 via Multi-Parameter Detection. Frontiers in Immunology, 2021, 12, 614676.	4.8	13
43	Early Infection HIV-1 Envelope V1-V2 Genotypes Do Not Enhance Binding or Replication in Cells Expressing High Levels of $\hat{l}\pm4\hat{l}^2$ 7 Integrin. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 64, 249-253.	2.1	9
44	Brief Report: Pulmonary Tuberculosis Is Associated With Persistent Systemic Inflammation and Decreased HIV-1 Reservoir Markers in Coinfected Ugandans. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 407-411.	2.1	8
45	Condylomata Acuminata (Anogenital Warts) Contain Accumulations of HIV-1 Target Cells That May Provide Portals for HIV Transmission. Journal of Infectious Diseases, 2019, 219, 275-283.	4.0	6
46	The Effect of IL-6 Inhibitors on Mortality Among Hospitalized COVID-19 Patients: A Multicenter Study. Journal of Infectious Diseases, 2021, 223, 581-588.	4.0	6
47	Integrase Inhibitor Use Associated with Weight Gain in Women and Incident Diabetes Mellitus. AIDS Research and Human Retroviruses, 2022, 38, 208-215.	1.1	6
48	Antibody-dependent cellular cytotoxicity responses and susceptibility influence HIV-1 mother-to-child transmission. JCI Insight, 2022, 7, .	5.0	5
49	Antibodies and Acidic Environment Do Not Enhance HIV-1 Transcytosis. Journal of Infectious Diseases, 2016, 214, 1221-1224.	4.0	4
50	A new cell line for assessing HIV-1 antibody dependent cellular cytotoxicity against a broad range of variants. Journal of Immunological Methods, 2020, 480, 112766.	1.4	4
51	Clinical implications of new findings in HIV basic research. HIV Therapy, 2009, 3, 351-360.	0.6	2
52	Family matters for coronavirus disease and vaccines. Journal of Clinical Investigation, 2021, 131, .	8.2	2
53	Vertical HIV-1 Transmission in the Setting of Maternal Broad and Potent Antibody Responses. Journal of Virology, 2022, 96, e0023122.	3.4	2
54	Neutralization and beyond: Antibodies and HIV-1 acquisition. Current Topics in Virology, 2018, 15, 73-86.	0.0	1

#	Article	IF	CITATIONS
55	Title is missing!. , 2020, 15, e0243888.		O
56	Title is missing!. , 2020, 15, e0243888.		0
57	Title is missing!. , 2020, 15, e0243888.		O
58	Title is missing!. , 2020, 15, e0243888.		0